Posted by Michael Wonder on 08 Feb 2023
Novartis CEO Narasimhan suggests possible legislative action to reverse Inflation Reduction Act’s impact on drug prices: what can and can’t be done
7 February 2023 - It’s no secret that the pharmaceutical industry aims to blunt the Inflation Reduction Act’s effects, specifically the downward pressure on the prices of existing prescription drugs.
Last week, in an earnings call with investors, Novartis CEO Vas Narasimhan - and incoming chairman of the board for the powerful lobby group PhRMA - pledged to work on undoing certain facets of the Act's drug pricing provisions.
